The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.
McKesson added a new governance and sustainability risk while removing its vaccination distribution risk, reflecting a shift from pandemic-related concerns to longer-term environmental and social regulatory pressures. The company substantially modified eight existing risks, with notable revisions to cybersecurity and data protection disclosures, tax position vulnerabilities, strategic growth execution, talent retention challenges, and supplier relationships. The 30 unchanged risks indicate that core operational and market risks remain the primary focus of McKesson's risk disclosure strategy.
Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.
🟢 New in Current Filing
Governance issues and regulations, including those related to social issues, climate change, and sustainability, and stakeholder response thereto may have an adverse effect on our business, financial condition, and results of operations and damage our reputation.
🔒
🟢 New in Current Filing
McKESSON CORPORATION
🔒
🔴 No Match in Current Filing
Our participation in vaccination distribution programs may materially affect our operating results, reputation, and business.
🔒
🔴 No Match in Current Filing
McKESSON CORPORATION
🔒
🟡 Modified
We experience cybersecurity incidents that might significantly compromise our technology systems or might result in material data breaches.
🔒
🟡 Modified
Privacy, data protection, and cybersecurity laws increase our compliance burden.
🔒
🟡 Modified
We might be adversely impacted by tax legislation or challenges to our tax positions.
🔒
🟡 Modified
We may be unsuccessful in achieving our strategic growth objectives.
🔒
🟡 Modified
We might be unable to successfully recruit and retain qualified employees.
🔒
🟡 Modified
We might lose our ability to purchase, compound, store, or distribute pharmaceuticals and controlled substances.
🔒
🟡 Modified
We might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models.
🔒
🟡 Modified
We are impacted by customer purchase reductions, contract non-renewals, payment defaults, and bankruptcies.
🔒